Erythropoietin Drugs Market – By Drug Class (Biologics and Biosimilar), By Product (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa, and Others), By Applications (Cancer, Haematology, Renal Diseases, and Neurology), and By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Erythropoietin Drugs Market is accounted approximate USD 8.9 billion in 2020 and it is expected to reach approximate USD 27.8 million by 2030 with a CAGR of 12.1% during forecast period.Erythropoietin is a glycoprotein hormone released by the human renal system. This hormone helps in the production of red blood cells that carry oxygen from the lungs to the various parts of the body. Erythropoietin drugs control the process of erythropoiesis, i.e. the production of red blood cells. These drugs are mainly used in the treatment of chemotherapy-induced anaemia, cancer, and HIV. The growing population across the globe along with increasing HIV, cancer, and chronic renal diseases is the major factor driving the erythropoietin drugs market worldwide.

Market Segmentation:

On the basis of the class of drugs, the erythropoietin drugs market can be bifurcated into biologics and biosimilar. Based on product, the market is segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to applications, the erythropoietin drugs market can be classified into cancer, haematology, renal diseases, and neurology. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.

Market Dynamics and Factors:

The increasing number of patients suffering from anaemic conditions due to HIV, cancer, and end-stage renal diseases (ESRD), favourable reimbursements, and the rapid commercialisation of erythropoietin drugs are the major factors driving the growth of the erythropoietin drugs market. For instance, according to Centres for Disease Control and Prevention (CDC), around 5.5 million ambulatory care patients suffer from anaemia due to nutritional deficiency, while chronic disease is the second most dominant cause. The surge in drug patent expiration has increased the emphasis on the usage of biosimilar medicines having the same therapeutic effect with lower cost. This is another key factor that will fuel the growth of the erythropoietin drugs market in the coming future. Other major factors driving the global erythropoietin drugs market include inactive lifestyles attributing to deficiencies in iron, vitamin B12, and folic acid resulting in anaemic conditions; increase in blood transfusion during surgeries and treatments; and rising geriatric population. However, high costs of erythropoietin drugs and longer duration of treatments are some restraining factors that may hinder the growth of the market to some extent. 

Geographic Analysis:

North America is expected to be the most dominant region for erythropoietin drugs in terms of revenue market share during the forecast period. Growing incidences of chronic kidney diseases (CDK), cancer, and HIV; presence of excellent healthcare facilities; and increasing investments in novel drug discoveries are some of the major factors responsible for the market dominance of the North American region. For instance, in the U.S, around 20 million people suffer from chronic kidney diseases out of which 2-4 million are having anaemia. The presence of major erythropoietin drug manufacturers in North America further enhances the growth of the market in the region. The existence of a significant amount of geriatric population in the European region has made it the second most dominant market for erythropoietin drugs. The Asia Pacific region is anticipated to be the fastest growing market for erythropoietin drugs during the forecast period. The rapid development in healthcare infrastructure, enhanced purchasing power, rising medical tourism are certain factors attributing towards the market growth in the APAC region. Rising prevalence of chronic diseases in the APAC region presents a lucrative opportunity for biosimilars with low cost of therapy in the region. 

Competitive Scenario:

The key players operating in the global erythropoietin drugs market are –

Johnson & Johnson, Roche Holding AG, Biocon Limited, Celltrion Inc., LG Life Sciences Ltd., Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd. 

Erythropoietin Drugs Market Report Scope